BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 26493127)

  • 1. Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
    Ahlbrecht J; Martino F; Pul R; Skripuletz T; Sühs KW; Schauerte C; Yildiz Ö; Trebst C; Tasto L; Thum S; Pfanne A; Roesler R; Lauda F; Hecker M; Zettl UK; Tumani H; Thum T; Stangel M
    Mult Scler; 2016 Aug; 22(9):1202-14. PubMed ID: 26493127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome.
    Sladkova V; Mareš J; Lubenova B; Zapletalova J; Stejskal D; Hlustik P; Kanovsky P
    Neurol Res; 2011 May; 33(4):415-20. PubMed ID: 21535941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of the C-X-C motif chemokine ligand 13 and interleukin-8 in predicting the transition from clinically isolated syndrome to multiple sclerosis.
    Klíčová K; Mareš J; Sobek O; Rous Z; Rous M; Raška M; Hartung HP
    Eur J Neurosci; 2024 Jun; 59(11):2955-2966. PubMed ID: 38453679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.
    Tumani H; Lehmensiek V; Rau D; Guttmann I; Tauscher G; Mogel H; Palm C; Hirt V; Suessmuth SD; Sapunova-Meier I; Ludolph AC; Brettschneider J
    Neurosci Lett; 2009 Mar; 452(2):214-7. PubMed ID: 19383442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum and cerebrospinal fluid prolactin levels in male and female patients with clinically-isolated syndrome or relapsing-remitting multiple sclerosis.
    Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Sfagos C
    J Neuroendocrinol; 2010 Jun; 22(6):503-8. PubMed ID: 20236233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.
    Brettschneider J; Petzold A; Junker A; Tumani H
    Mult Scler; 2006 Apr; 12(2):143-8. PubMed ID: 16629417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome.
    Thouvenot E; Hinsinger G; Demattei C; Uygunoglu U; Castelnovo G; Pittion-Vouyovitch S; Okuda D; Kantarci O; Pelletier D; Lehmann S; Marin P; Siva A; Lebrun C
    Mult Scler; 2019 Apr; 25(5):669-677. PubMed ID: 29564952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study.
    Zanghì A; Manuti V; Serviddio G; D'Amico E; Avolio C
    Front Immunol; 2023; 14():1226130. PubMed ID: 37711630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing.
    Keller A; Leidinger P; Steinmeyer F; Stähler C; Franke A; Hemmrich-Stanisak G; Kappel A; Wright I; Dörr J; Paul F; Diem R; Tocariu-Krick B; Meder B; Backes C; Meese E; Ruprecht K
    Mult Scler; 2014 Mar; 20(3):295-303. PubMed ID: 23836875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosis.
    Tamam Y; Gunes B; Akbayir E; Kizilay T; Karaaslan Z; Koral G; Duzel B; Kucukali CI; Gunduz T; Kurtuncu M; Yilmaz V; Tuzun E; Turkoglu R
    Mult Scler Relat Disord; 2021 Feb; 48():102697. PubMed ID: 33352356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome.
    Orbach R; Gurevich M; Achiron A
    Mult Scler; 2014 Jan; 20(1):35-42. PubMed ID: 23722323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxylipins in cerebrospinal fluid in clinically isolated syndrome and relapsing remitting multiple sclerosis.
    Håkansson I; Gouveia-Figueira S; Ernerudh J; Vrethem M; Ghafouri N; Ghafouri B; Nording M
    Prostaglandins Other Lipid Mediat; 2018 Sep; 138():41-47. PubMed ID: 30118859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
    Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.
    Cantó E; Tintoré M; Villar LM; Costa C; Nurtdinov R; Álvarez-Cermeño JC; Arrambide G; Reverter F; Deisenhammer F; Hegen H; Khademi M; Olsson T; Tumani H; Rodríguez-Martín E; Piehl F; Bartos A; Zimova D; Kotoucova J; Kuhle J; Kappos L; García-Merino JA; Sánchez AJ; Saiz A; Blanco Y; Hintzen R; Jafari N; Brassat D; Lauda F; Roesler R; Rejdak K; Papuc E; de Andrés C; Rauch S; Khalil M; Enzinger C; Galimberti D; Scarpini E; Teunissen C; Sánchez A; Rovira A; Montalban X; Comabella M
    Brain; 2015 Apr; 138(Pt 4):918-31. PubMed ID: 25688078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
    Håkansson I; Tisell A; Cassel P; Blennow K; Zetterberg H; Lundberg P; Dahle C; Vrethem M; Ernerudh J
    Eur J Neurol; 2017 May; 24(5):703-712. PubMed ID: 28261960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis.
    Keller A; Leidinger P; Meese E; Haas J; Backes C; Rasche L; Behrens JR; Pfuhl C; Wakonig K; Gieß RM; Jarius S; Meder B; Bellmann-Strobl J; Paul F; Pache FC; Ruprecht K
    J Neuroinflammation; 2015 Oct; 12():196. PubMed ID: 26521232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis.
    Sellebjerg F; Royen L; Soelberg Sørensen P; Oturai AB; Jensen PEH
    Mult Scler; 2019 Oct; 25(11):1444-1451. PubMed ID: 30113249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid pleocytosis in multiple sclerosis patients with lesions showing reduced diffusion.
    Eisele P; Szabo K; Griebe M; Wolf ME; Hennerici MG; Gass A
    Mult Scler; 2014 Sep; 20(10):1391-5. PubMed ID: 24323819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis.
    Avsar T; Korkmaz D; Tütüncü M; Demirci NO; Saip S; Kamasak M; Siva A; Turanli ET
    Mult Scler; 2012 Aug; 18(8):1081-91. PubMed ID: 22252467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.